Gone Vegan.
Capsugel® HPMC portfolio

Contact us: solutions.emea@lonza.com  |   www.capsugel.com

Non-animal based alternative   |   Broadest HPMC offering  |  Capsugel® quality and performance

Lonza makes no warranties or representations of accuracy or completeness. All trademarks belong to Lonza or its affiliates.

Vcaps® Plus

The gold standard in HPMC capsules

Properties

  • HPMC only Capsules
  • No gelling agents
  • Improved physical and operational features to match the needs of the pharmaceutical industry

01

Dissolution profile

  • pH-independent performance 
  • Independent of ionic strength

02

Key advantages

  • Great visual appearance
  • Low-moisture content suitable for moisture-sensitive ingredients
  • Great machinability

03

More on Vcaps® plus

Vcaps® Enteric

 Right on target

Proven Properties

  • Intrinsically enteric capsule 
  • Improving tolerability of API’s that cause gastric-irritation 
  • API protection against degradation in the gastric environment
  • Achieving targeted release in the small intestine

01

In vitro dissolution test

  • Complies with pharmacopoeial requirements for delayed release
  • Robust enteric release 
  • Immediate and full disintegration at pH 6.8

02

Key advantages

  • Saves development time
  • No coating needed
  • High API protection

03

More on Vcaps® Enteric

Go to article: Home | Mapping the MindGo to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: EditorialGo to article: Biocorp Company InsightGo to article: BiocorpGo to article: ContentsGo to article: Fisher Clinical ServicesGo to article: Malvern Panalytical Company InsightGo to article: Malvern PanalyticalGo to article: NewsGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The Pharma Industry BriefingGo to article: Mattler ToledoGo to article: MedelpharmGo to article: HPV vaccines: a decade of progressGo to article: Nipro PharmaPackagingGo to article: PfanstiehlGo to article: Hereditary Alzheimer’s: could rare genes hold the clue to a cure?Go to article: SGSGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: Could a unique brain fingerprint predict a drug’s effectiveness?Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Genetic studies: a powerful tool for testing combination therapiesGo to article: Nelson Lab Company InsightGo to article: Nelson LabGo to article: Abiogen PharmaGo to article: The Express Scripts story; super-pharmacies and the US drug industryGo to article: B Medical SystemsGo to article: Daiichi JitsugyoGo to article: LaudaGo to article: Is a lack of female participants skewing heart disease trial results?Go to article: EcocoolGo to article: HOF SonderanlagenbauGo to article: DiverseyGo to article: Why the German Centre for Diabetes Research changed its approach to handling dataGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: QualiMetriXGo to article: How digital innovation is helping to drive transformation in regulatory affairs Go to article: DryceGo to article: ILC Dover IncGo to article: Pall BiotechGo to article: EventsGo to article: Event: Pharmpack EuropeGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: Unither PharmaceuticalsGo to article: Next issueGo to article: ButterworthGo to article: myLiquitab